Analysis of the Efficacy of Two Treatment Protocols for Patients With Symptomatic Oral Lichen Planus
Trial Snapshot
- Phase
- Not Applicable
- Status
- Completed
- Sponsor
- University of Messina
- Enrollment
- 61
- Locations
- 1
- Primary Endpoint
- Clinical Mucosal healing
Study Overview
Brief Summary
The primary objective of this study was to compare the therapeutic efficacy of clobetasol propionate 0.05% oral gel versus an anti-inflammatory mouthwash in an oral solution for the management of patients suffering from symptomatic OLP. The secondary objective was to analyze which one of the two treatments induced a greater risk of developing side effects.
Detailed Description
Forty patients were assigned (20 patients per group), through a randomized design, to receive clobetasol (clobetasol gel 0.05%), or an anti-inflammatory mouthwash (mouthwash which contains calcium hydroxide, hyaluronic acid, Umbelliferone and Oligomeric Proanthocyanidins) for 3-months. At baseline (T0) and after 3 months (T1), patients were subjected to clinical and oral assessments and were evaluated for the symptoms (Numerical Pain Scale, NRS score) and signs (Thongprasom's score) of OLP. Data were calculated using T-test for the dependent variable, Wilcoxon test and Mann-Witney u test.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Treatment
- Masking
- Single (Participant)
Eligibility Criteria
- Ages
- 25 Years to 70 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- •age ≥ 18 years;
- •clinical diagnosis and histological diagnosis of OLP on the basis of WHO criteria;
- •presence of symptoms related to OLP.
Exclusion Criteria
- •presence of systemic conditions that may have affected the study results;
- •state of pregnancy or breastfeeding;
- •histological signs of dysplasia;
- •drugs inducing a lichen response (ACE-inhibitors, β-blockers, etc.);
- •treatment of OLP in the six months prior to the start of the programme;
- •presence of extraoral lesions (genital, skin and other)
- •history of previous immunodeficiency or HIV seropositivity;
- •previous allogeneic bone marrow transplantation;
- •presence of systemic lupus erythematosus or other autoimmune diseases.
Arms & Interventions
Clobetasol treatment
The clobetasol group was treated with clobetasol propionate 0.05%, while the anti-inflammatory group was treated with mouthwash. The drug used consisted of Clobetasol propionate 0.05%, Ethyl alcohol 96° (50%), Hydroxyethylcellulose (4%); Preserved water (just enough to 100%) that was topically applied [11]. This drug was produced as a galenic formulation. Clobetasol propionate twice a day (every 12 hours) to the lesions with a soft bristle brush and were advised not to drink or eat during the hour following application of the medication.
Intervention: Healing evaluation (Drug)
Anti-inflammatory mouthwash
In patients of the anti-inflammatory group, the mouthwash was used pure and without dilution at a dosage of 20 ml 3 times a day, immediately after normal daily oral hygiene was prescribed. It contains calcium hydroxide, hyaluronic acid, Umbelliferone and Oligomeric Proanthocyanidins. Patients were instructed to rinse for at least 5 minutes over the entire oral mucosa, with particular emphasis on the regions where the lesions are located.
Intervention: Healing evaluation (Drug)
Outcomes
Primary Outcomes
Clinical Mucosal healing
Time Frame: 180 days
Patients clinically were evaluated using the scale used by Thongprasom et al. as reference. This gives a score that varies from 0 to 5, using a millimetre reference: 0, in the absence of lesions; 1, in the presence of hyperkeratosis streaks; 2, in the presence of an atrophic area less than 1 mm2; 3, in the presence of an atrophic area greater than 1 mm2; 4, in the presence of an erosive area less than 1 mm2; 5, in the presence of an erosive area greater than 1 mm2. In the presence of multiple injuries, the value has been calculated by summing the values of each injury.
Secondary Outcomes
No secondary outcomes reported
Investigators
Gaetano Isola, DDS, PhD
Researcher
University of Messina